1-(1H-1,2,3-benzotriazol-5-yl)methanamine monohydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-(1H-1,2,3-benzotriazol-5-yl)methanamine monohydrochloride
• 英文别名: 5-aminomethyl-1,2,3-benzotriazole hydrochloride；2H-benzotriazol-5-ylmethanamine;hydrochloride
• 化学式: C₇H₈N₄*ClH
• 分子量: 184.628
• InChiKey: MJQMWCMKYZLHCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.84
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  67.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(1H-1,2,3-benzotriazol-5-yl)methanamine monohydrochloride 、 4-叔-丁基苄基异硫氰酸酯 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-(1H-Benzotriazol-5-ylmethyl)-3-(4-tert-butyl-benzyl)-thiourea
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790
• 作为产物：
  描述：

  1H-苯并[d][1,2,3]噻唑-5-甲醛 在 palladium on activated charcoal 盐酸 、 盐酸羟胺 、 氢气 、 sodium acetate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 1-(1H-1,2,3-benzotriazol-5-yl)methanamine monohydrochloride
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790

文献信息

• Thrombin inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06610692B1

  公开（公告）日：2003-08-26

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2 or N; d is CY3 or N; e is CY4 or N; f is CY5 or N; g is CY6 or N; Y4, Y5, and Y6 are independently hydrogen, C1-4 alkyl, or halogen; Y1 and Y2 are independently hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy, and Y3 is hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, —CN, NH2, OH or C1-4 alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.

  发明的化合物在抑制凝血酶和相关血栓闭塞方面具有以下结构：或其药学上可接受的盐，其中b为NY或O；c为CY2或N；d为CY3或N；e为CY4或N；f为CY5或N；g为CY6或N；Y4、Y5和Y6独立地为氢、C1-4烷基或卤素；Y1和Y2独立地为氢、C1-4烷基、C3-7环烷基、卤素、NH2、OH或C1-4烷氧基，Y3为氢、C1-4烷基、C3-7环烷基、卤素、—CN、NH2、OH或C1-4烷氧基；A为，并且W、W1、R1、R3、R4、R5、X和Z在规范中有定义。
• THROMBIN INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1124822A1

  公开（公告）日：2001-08-22
• EP1124822A4
  申请人：——

  公开号：EP1124822A4

  公开（公告）日：2002-04-03
• US6610692B1
  申请人：——

  公开号：US6610692B1

  公开（公告）日：2003-08-26
• [EN] THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE
  申请人：MERCK & CO INC

  公开号：WO2000026211A1

  公开（公告）日：2000-05-11

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the structure (I) or a pharmaceutically acceptable salt thereof, wherein b is NY1 or O; c is CY2 or N; d is CY3 or N; e is CY4 or N; f is CY5 or N; g is CY6 or N; Y?4, Y5, and Y6¿ are independently hydrogen, C¿1-4? alkyl, or halogen; Y?1 and Y2¿ are independently hydrogen, C¿1-4? alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy, and Y?3¿ is hydrogen, C¿1-4? alkyl, C3-7 cycloalkyl, halogen, -CN, NH2, OH or C1-4 alkoxy; A is (II), (III), (IV), (V) or (VI); and W, W?1, R1, R3, R4, R5¿, X and Z are defined in the specification.